@entity117 in the primary prophylaxis of @entity1211 in surgical XXXX .

@entity1 @entity548 @entity117 @entity1211 @entity7943
INTRODUCTION: @entity1211 ( @entity1211 ) is a common complication in surgical @entity1 , especially those undergoing lower limb orthopaedic procedures as well as oncological resectional surgery. Numerous studies have evaluated the role of @entity117 ( @entity7943 , @entity117 ) in primary @entity1211 prevention, with contradictory results reflected in divergent guidelines. We reviewed current evidence for @entity7943 as primary @entity1211 . METHODS: English language studies meeting our inclusion criteria were retrieved from PubMed, EMBASE and Cochrane databases. Six studies (3 meta-analyses and 3 randomized trials) comparing @entity7943 with placebo and 7 studies (1 meta-analysis, 5 randomized trials, and 1 prospective) comparing @entity7943 with other anticoagulants were included in the final analysis. Retrospective studies and case reports were excluded. RESULTS: @entity7943 is more effective than placebo in primary @entity1211 prevention. Although there is clinical equipoise when @entity7943 is compared with other anticoagulants, studies specific to orthopaedic surgery suggest that @entity7943 appears as effective as low molecular weight heparin (LMWH) and may reduce @entity548 risk. Extended prophylaxis up to 4 weeks post surgery reduces @entity1211 episodes. CONCLUSIONS: @entity7943 may be considered as a potential strategy in primary @entity1211 in orthopaedic @entity1 at high-risk of @entity548 complications. Further studies comparing @entity7943 with LMWH/oral anticoagulants in primary thromboprophylaxis following non-orthopaedic surgery are warranted.
